Multiple sclerosis - candidate mechanisms underlying CNS atrophy

Trends in Neurosciences

Volumn 33, Issue 4, 2010, Pages 202-210

  Siffrin, Volker ^a,b   Vogt, Johannes ^a   Radbruch, Helena ^b   Nitsch, Robert ^a   Zipp, Frauke ^a,b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC ENCEPHALOMYELITIS; AXONAL INJURY; BRAIN ATROPHY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DEGENERATIVE DISEASE; DEMYELINATION; DENDRITE; DISEASE COURSE; HUMAN; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIKARYON; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ATROPHY; AXONS; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEURONS;

EID: 77950862182     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2010.01.002     Document Type: Review

References (121)

1. Zipp F., Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci. 2006, 29:518-527.
2. Ferguson B., et al. Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120:393-399.
3. Kornek B., et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 2000, 157:267-276.
4. Trapp B.D., et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
5. Cifelli A., et al. Thalamic neurodegeneration in multiple sclerosis. Ann. Neurol. 2002, 52:650-653.
6. Gilmore C.P., et al. Spinal cord neuronal pathology in multiple sclerosis. Brain Pathol. 2008, 19:642-649.
7. Papadopoulos D., et al. Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis. Brain Pathol. 2009, 19:238-253.
8. Peterson J.W., et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 2001, 50:389-400.
9. Vercellino M., et al. Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J. Neuropathol. Exp. Neurol. 2007, 66:732-739.
10. Vogt J., et al. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann. Neurol. 2009, 66:310-322.
11. Wegner C., et al. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006, 67:960-967.
12. Fisher E., et al. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann. Neurol. 2008, 64:255-265.
13. Fisher E., et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002, 59:1412-1420.
14. Rudick R.A., et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999, 53:1698-1704.
15. Brex P.A., et al. Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2001, 70:544-547.
16. Chard D.T., et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002, 125:327-337.
17. Barkhof F., et al. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat. Rev. Neurol. 2009, 5:256-266.
18. Matthews P.M., et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996, 119:715-722.
19. Richards T.L. Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy. Am. J. Roentgenol. 1991, 157:1073-1078.
20. Bjartmar C., et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 2000, 48:893-901.
21. De Stefano N., et al. In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 1999, 122:1933-1939.
22. Kuhlmann T., et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002, 125:2202-2212.
23. Sailer M., et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain 2003, 126:1734-1744.
24. Wylezinska M., et al. Thalamic neurodegeneration in relapsing-remitting multiple sclerosis. Neurology 2003, 60:1949-1954.
25. Gilmore C.P., et al. Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J. Neurol. Neurosurg. Psychiatry 2009, 80:182-187.
26. Kutzelnigg A., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.
27. Bo L., et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult. Scler. 2003, 9:323-331.
28. Bo L., et al. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol. 2003, 62:723-732.
29. Koyanagi I., et al. Three-dimensional analysis of the vascular system in the rat spinal cord with scanning electron microscopy of vascular corrosion casts. Part 1: Normal spinal cord. Neurosurgery 1993, 33:277-283.
30. Tonra J.R. Cerebellar susceptibility to experimental autoimmune encephalomyelitis in SJL/J mice: potential interaction of immunology with vascular anatomy. Cerebellum 2002, 1:57-68.
31. Hoffmann S., et al. Cognitive impairment in multiple sclerosis. Curr. Opin. Neurol. 2007, 20:275-280.
32. Mainero C., et al. fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis. Neuroimage 2004, 21:858-867.
33. Staffen W., et al. Cognitive function and fMRI in patients with multiple sclerosis: evidence for compensatory cortical activation during an attention task. Brain 2002, 125:1275-1282.
34. Ben Nun A., et al. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 1981, 292:60-61.
35. Gold R., et al. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
36. Nimmerjahn A., et al. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
37. Remington L.T., et al. Microglial recruitment, activation, and proliferation in response to primary demyelination. Am. J. Pathol. 2007, 170:1713-1724.
38. Trapp B.D., et al. Evidence for synaptic stripping by cortical microglia. Glia 2007, 55:360-368.
39. Ransohoff R.M., Perry V.H. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 2009, 27:119-145.
40. Heppner F.L., et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 2005, 11:146-152.
41. Diestel A., et al. Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. J. Exp. Med. 2003, 198:1729-1740.
42. + T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 2000, 192:393-404.
43. Traugott U., et al. Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science 1983, 219:308-310.
44. Hu D., et al. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat. Immunol. 2004, 5:516-523.
45. Bitsch A., et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000, 123:1174-1183.
46. Mars L.T., et al. CD8 T cell responses to myelin oligodendrocyte glycoprotein-derived peptides in humanized HLA-A0201-transgenic mice. J. Immunol. 2007, 179:5090-5098.
47. Neumann H., et al. Induction of MHC class I genes in neurons. Science 1995, 269:549-552.
48. Medana I., et al. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am. J. Pathol. 2001, 159:809-815.
49. Siffrin V., et al. New insights into adaptive immunity in chronic neuroinflammation. Adv. Immunol. 2007, 96:1-40.
50. Kamradt T., Mitchison N.A. Advances in immunology: Tolerance and autoimmunity. N. Engl. J. Med. 2001, 344:655-664.
51. Perez-Diez A., et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007, 109:5346-5354.
52. Nitsch R., et al. Direct impact of T cells on neurons revealed by two-photon microscopy in living brain tissue. J. Neurosci. 2004, 24:2458-2464.
53. Aktas O., et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 2005, 46:421-432.
54. Nitsch R., et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 2000, 356:827-828.
55. Liu Y.W., et al. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat. Med. 2006, 12:518-525.
56. Arnold D.L., et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann. Neurol. 1994, 36:76-82.
57. De Stefano N., et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998, 121:1469-1477.
58. Griffiths I., et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 1998, 280:1610-1613.
59. Irvine K.A., Blakemore W.F. Remyelination protects axons from demyelination-associated axon degeneration. Brain 2008, 131:1464-1477.
60. Trapp B.D., Stys P.K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 2009, 8:280-291.
61. 2+ exchanger. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8168-8173.
62. Mahad D.J., et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009, 132:1161-1174.
63. Edgar J.M., et al. Oligodendroglial modulation of fast axonal transport in a mouse model of hereditary spastic paraplegia. J. Cell Biol. 2004, 166:121-131.
64. Kassmann C.M., et al. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat. Genet. 2007, 39:969-976.
65. Rivera-Quinones C., et al. Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. Nat. Med. 1998, 4:187-193.
66. Ure D.R., Rodriguez M. Preservation of neurologic function during inflammatory demyelination correlates with axon sparing in a mouse model of multiple sclerosis. Neuroscience 2002, 111:399-411.
67. Miller D.H., et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002, 125:1676-1695.
68. Arnold D.L., et al. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann. Neurol. 1992, 31:235-241.
69. Narayanan S., et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann. Neurol. 1997, 41:385-391.
70. Deluca G.C., et al. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 2004, 127:1009-1018.
71. Prozorovski T., et al. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat. Cell Biol. 2008, 10:385-394.
72. Mi S., et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 2007, 13:1228-1233.
73. Franklin R.J., ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat. Rev. Neurosci. 2008, 9:839-855.
74. Matthews M.R., et al. Transneuronal Cell Degeneration in the Lateral Geniculate Nucleus of the Macaque Monkey. J. Anat. 1960, 94:145-168.
75. Eidelberg E., et al. Transsynaptic degeneration of motoneurones caudal to spinal cord lesions. Brain Res. Bull. 1989, 22:39-45.
76. Stelzner D.J., et al. Effects of spinal transection in neonatal and weanling rats: survival of function. Exp. Neurol. 1975, 46:156-177.
77. McBride R.L., Feringa E.R. Ventral horn motoneurons 10, 20 and 52 weeks after T-9 spinal cord transection. Brain Res. Bull. 1992, 28:57-60.
78. Bjugn R., et al. Spinal cord transection - no loss of distal ventral horn neurons. Modern stereological techniques reveal no transneuronal changes in the ventral horns of the mouse lumbar spinal cord after thoracic cord transection. Exp. Neurol. 1997, 148:179-186.
79. Bannerman P.G., et al. Motor neuron pathology in experimental autoimmune encephalomyelitis: studies in THY1-YFP transgenic mice. Brain 2005, 128:1877-1886.
80. Zhu B., et al. Dendritic and synaptic pathology in experimental autoimmune encephalomyelitis. Am. J. Pathol. 2003, 162:1639-1650.
81. McComas A.J., et al. 'Sick' motoneurones. A unifying concept of muscle disease. Lancet 1971, 1:321-326.
82. Chang C.W. Evident transsynaptic degeneration of motor neurons after spinal cord injury: a study of neuromuscular jitter by axonal microstimulation. Am. J. Phys. Med. Rehabil. 1998, 77:118-121.
83. Xiong G.X., et al. Motor unit number estimation of the tibialis anterior muscle in spinal cord injury. Spinal Cord 2008, 46:696-702.
84. Tower S.S. Pyramidal lesion in the monkey. Brain 1940, 63:36-90.
85. van Alphen H., et al. [On a remarkable reaction of the motor neurons of the lumbosacral region after a traumatic cervical transsection in a man.]. Neurochirurgie 1962, 8:328-330.
86. Khoubesserian P., et al. Motor unit changes in traumatic paraplegia. Revue Neurologique 1983, 139:635-642.
87. Kaelan C., et al. An investigation of possible transynaptic neuronal degeneration in human spinal cord injury. J. Neurol. Sci. 1988, 86:231-237.
88. Jimenez O., et al. A histopathological analysis of the human cervical spinal cord in patients with acute traumatic central cord syndrome. Spinal Cord 2000, 38:532-537.
89. Fouad K., et al. Cervical sprouting of corticospinal fibers after thoracic spinal cord injury accompanies shifts in evoked motor responses. Curr. Biol. 2001, 11:1766-1770.
90. Kuang R.Z., Kalil K. Specificity of corticospinal axon arbors sprouting into denervated contralateral spinal cord. J. Comp. Neurol. 1990, 302:461-472.
91. Feringa E.R., et al. Retrograde transport in corticospinal neurons after spinal cord transection. Neurology 1983, 33:478-482.
92. Barron K.D., et al. Neurons of layer Vb of rat sensorimotor cortex atrophy but do not die after thoracic cord transection. J. Neuropathol. Exp. Neurol. 1988, 47:62-74.
93. Ramirez L.F., Kalil K. Critical stages for growth in the development of cortical neurons. J. Comp. Neurol. 1985, 237:506-518.
94. Kalil K., Schneider G.E. Retrograde cortical and axonal changes following lesions of the pyramidal tract. Brain Res. 1975, 89:15-27.
95. Feringa E.R., et al. The orthograde flow of tritiated proline in corticospinal neurons at various ages and after spinal cord injury. J. Neurol. Neurosurg. Psychiatry 1984, 47:917-920.
96. Feringa E.R., et al. Loss of neurons in the red nucleus after spinal cord transection. Exp. Neurol. 1988, 100:112-120.
97. Goshgarian H.G., et al. Cell death and changes in the retrograde transport of horseradish peroxidase in rubrospinal neurons following spinal cord hemisection in the adult rat. J. Comp. Neurol. 1983, 214:251-257.
98. McBride R.L., et al. Prelabeled red nucleus and sensorimotor cortex neurons of the rat survive 10 and 20 weeks after spinal cord transection. J. Neuropathol. Exp. Neurol. 1989, 48:568-576.
99. Peterson G.M., et al. Identified septohippocampal neurons survive axotomy: a fine-structural analysis in the rat. Neurosci. Lett. 1992, 138:81-85.
100. Peterson G.M., et al. Light- and electron-microscopic studies of identified septohippocampal neurons surviving axotomy. Ann. N. Y. Acad. Sci. 1993, 679:291-298.
101. Rossignol S., et al. Spinal cord injury: time to move?. J. Neurosci. 2007, 27:11782-11792.
102. Pruitt J.N., et al. Corticospinal axons persist in cervical and high thoracic regions 10 weeks after a T-9 spinal cord transection. Neurology 1988, 38:946-950.
103. Fishman P.S. Retrograde changes in the corticospinal tract of posttraumatic paraplegics. Arch. Neurol. 1987, 44:1082-1084.
104. Bernstein J.J., Bernstein M.E. Axonal regeneration and formation of synapses proximal to the site of lesion following hemisection of the rat spinal cord. Exp. Neurol. 1971, 30:336-351.
105. Fishman P.S., Kelley J.P. The fate of severed corticospinal axons. Neurology 1984, 34:1161-1167.
106. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder? Annu. Rev. Neurosci. 2008, 31:247-269.
107. Brunn A., et al. CD4 T cells mediate axonal damage and spinal cord motor neuron apoptosis in murine p0106-125-induced experimental autoimmune neuritis. Am. J. Pathol. 2008, 173:93-105.
108. Adams R.D., Kubik C.S. The morbid anatomy of the demyelinative diseases. Am. J. Med. 1952, 12:510-546.
109. De Stefano N., et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003, 60:1157-1162.
110. Gilmore C.P., et al. Spinal cord atrophy in multiple sclerosis caused by white matter volume loss. Arch. Neurol. 2005, 62:1859-1862.
111. Evangelou N., et al. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 2000, 123:1845-1849.
112. Ganter P., et al. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol. Appl. Neurobiol. 1999, 25:459-467.
113. Bjartmar C., et al. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 2001, 57:1248-1252.
114. Vercellino M., et al. Grey matter pathology in multiple sclerosis. J. Neuropathol. Exp. Neurol. 2005, 64:1101-1107.
115. Naumann T., et al. Fine structure of rat septohippocampal neurons: II. A time course analysis following axotomy. J. Comp. Neurol. 1992, 325:219-242.
116. Scholz J., et al. Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury. J. Neurosci. 2005, 25:7317-7323.
117. Sofroniew M.V., Isacson O. Distribution of degeneration of cholinergic neurons in the septum following axotomy in different portions of the fimbria-fornix: a correlation between degree of cell loss and proximity of neuronal somata to the lesion. J. Chem. Neuroanat. 1988, 1:327-337.
118. Thanos S., et al. Treatment of the adult retina with microglia-suppressing factors retards axotomy-induced neuronal degradation and enhances axonal regeneration in vivo and in vitro. J. Neurosci. 1993, 13:455-466.
119. Cavanagh J.B. Dying back process - common denominator in many naturally occurring and toxic neuropathies. Arch. Pathol. Lab. Med. 1979, 103:659-664.
120. Lubinska L. Early course of Wallerian degeneration in myelinated fibers of rat phrenic-nerve. Brain Res. 1977, 130:47-63.
121. Pfenninger K.H. Plasma membrane expansion: a neuron's Herculean task. Nat. Rev. Neurosci. 2009, 10:251-261.